Grace Spencer
Nurse Practitioner · Birmingham, ALNPI 1285158170
Payments from drug & device makers
Across 97 payments — averaging $53.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Lilly USA, LLC$420
- Bayer$372
- Novo Nordisk$362
- Boehringer Ingelheim$268
- Sanofi-aventis U.S. LLC$215
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$77015%
- Travel & lodging$1,12522%
- Food & beverage$3,30764%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $2,514 |
| Lilly USA, LLC | 12 | $420 |
| Bayer | 4 | $372 |
| Novo Nordisk | 8 | $362 |
| Boehringer Ingelheim | 6 | $268 |
| Sanofi-aventis U.S. LLC | 10 | $215 |
| Radius Health, Inc. | 2 | $177 |
| Xeris Pharmaceuticals, Inc. | 4 | $155 |
| Abbott | 3 | $154 |
| Tandem Diabetes Care, Inc. | 6 | $121 |
| Dexcom, Inc. | 6 | $110 |
| BETA Bionics, Inc. | 5 | $93 |
| Amgen | 4 | $68 |
| IBSA Pharma Inc. | 3 | $54 |
| Insulet Corporation | 2 | $37 |
| AbbVie | 2 | $35 |
| Antares Pharma, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,241
- Minimed 770G System$770
- Kerendia$239
- Tymlos$128
- MOUNJARO$122
- Saxenda$117
- Wegovy$117
- FREESTYLE LIBRE 3$112
- JARDIANCE$109
How this compares
$5,202 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 392 | $453,390 |
| MounjaroTirzepatide | 246 | $289,776 |
| JardianceEmpagliflozin | 222 | $203,689 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 125 | $134,599 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $96,256 |
| Tresiba Flextouch U-200Insulin Degludec | 112 | $81,625 |
| TrulicityDulaglutide | 62 | $76,727 |
| Tresiba Flextouch U-100Insulin Degludec | 95 | $62,830 |
| KerendiaFinerenone | 72 | $58,729 |
| GlyxambiEmpagliflozin/Linagliptin | 67 | $52,896 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 44 | $45,641 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $34,679 |
| Gvoke Hypopen 2-PackGlucagon | 49 | $33,891 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 23 | $33,841 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $30,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog, Fiasp | $362 | $546,627540 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Tradjenta | $268 | $415,468449 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $420 | $384,220410 claims |
| BayerKerendia | $372 | $58,72972 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $215 | $45,64144 claims |
| MerckJanuvia | $15 | $20,84029 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $4,756364 claims |
| AbbVieSynthroid | $35 | $3,92754 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Birmingham
- Ginger McDanielBirmingham$27K
- Leah GravesBirmingham$21K
- Lauren DowneyBirmingham$19K
- Lisa PeoplesBirmingham$17K
- Samantha WeaverBirmingham$17K
- Logan GilmoreBirmingham$13K
- Jennifer CothronBirmingham$13K
- Chelsea KelleyBirmingham$13K
- Vanessa HillBirmingham$11K
- Heather BuffingtonBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.